SG11201404505PA - Pyridone derivative - Google Patents

Pyridone derivative

Info

Publication number
SG11201404505PA
SG11201404505PA SG11201404505PA SG11201404505PA SG11201404505PA SG 11201404505P A SG11201404505P A SG 11201404505PA SG 11201404505P A SG11201404505P A SG 11201404505PA SG 11201404505P A SG11201404505P A SG 11201404505PA SG 11201404505P A SG11201404505P A SG 11201404505PA
Authority
SG
Singapore
Prior art keywords
pyridone derivative
pyridone
derivative
Prior art date
Application number
SG11201404505PA
Inventor
Hitoshi Ohki
Masahiro Ota
Kosuke Takeuchi
Hideaki Watanabe
Akitake Yamaguchi
Yoshihiro Shibata
Yuichi Tominaga
Takeshi Jimbo
Keijiro Kobayashi
Katsuhiro Kobayashi
Daisuke Fukatsu
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201404505PA publication Critical patent/SG11201404505PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
SG11201404505PA 2012-01-31 2013-01-30 Pyridone derivative SG11201404505PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012017971 2012-01-31
US201261746039P 2012-12-26 2012-12-26
PCT/JP2013/052111 WO2013115280A1 (en) 2012-01-31 2013-01-30 Pyridone derivative

Publications (1)

Publication Number Publication Date
SG11201404505PA true SG11201404505PA (en) 2014-10-30

Family

ID=48905312

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404505PA SG11201404505PA (en) 2012-01-31 2013-01-30 Pyridone derivative

Country Status (30)

Country Link
US (1) US8933103B2 (en)
EP (1) EP2810937B1 (en)
JP (1) JP6006241B2 (en)
KR (1) KR102078530B1 (en)
CN (1) CN104185627B (en)
AU (1) AU2013216006B2 (en)
CA (1) CA2863515C (en)
CO (1) CO7071126A2 (en)
CY (1) CY1118656T1 (en)
DK (1) DK2810937T3 (en)
ES (1) ES2617484T3 (en)
HK (1) HK1203504A1 (en)
HR (1) HRP20170303T1 (en)
HU (1) HUE031624T2 (en)
IL (1) IL233863A (en)
LT (1) LT2810937T (en)
MX (1) MX351812B (en)
MY (1) MY165215A (en)
NZ (1) NZ627586A (en)
PH (1) PH12014501719B1 (en)
PL (1) PL2810937T3 (en)
PT (1) PT2810937T (en)
RS (1) RS55728B1 (en)
RU (1) RU2632885C2 (en)
SG (1) SG11201404505PA (en)
SI (1) SI2810937T1 (en)
SM (1) SMT201700065B (en)
TW (1) TWI537259B (en)
WO (1) WO2013115280A1 (en)
ZA (1) ZA201405486B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162061A1 (en) * 2012-04-26 2013-10-31 第一三共株式会社 Bicyclic pyrimidine compound
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
MX2016006815A (en) 2013-11-27 2016-12-02 Signalchem Lifesciences Corp Aminopyridine derivatives as tam family kinase inhibitors.
JP6783224B2 (en) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ Use of dianehydrogalactitol and its analogs or derivatives to treat non-small cell lung cancer and ovarian cancer
TWI690525B (en) 2014-07-07 2020-04-11 日商第一三共股份有限公司 Pyridone derivatives containing tetrahydropyranylmethyl group and use thereof
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
TWI828027B (en) 2016-03-28 2024-01-01 美商英塞特公司 Pyrrolotriazine compounds as tam inhibitors
CN108250200A (en) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 A kind of compound and its preparation and application with Axl inhibitory activity
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
KR20200088308A (en) 2017-09-27 2020-07-22 인사이트 코포레이션 Salts of pyrrolotriazine derivatives useful as TAM inhibitors
JP7223998B2 (en) 2017-10-13 2023-02-17 小野薬品工業株式会社 Solid cancer therapeutic agent containing an Axl inhibitor as an active ingredient
WO2019148125A1 (en) * 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
TWI827583B (en) 2018-03-08 2024-01-01 美商英塞特公司 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-γ INHIBITORS
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TW202005962A (en) * 2018-07-04 2020-02-01 日商第一三共股份有限公司 The manufacturing method of diarylpyridine derivatives
CN114364798A (en) 2019-03-21 2022-04-15 欧恩科斯欧公司 Combination of Dbait molecules with kinase inhibitors for the treatment of cancer
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN112625026B (en) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Quinoline derivatives of TAM family kinase inhibitors
US11753381B2 (en) 2019-09-27 2023-09-12 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
EP4065565A4 (en) * 2019-11-26 2023-12-06 Board of Regents, The University of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2022220227A1 (en) * 2021-04-14 2022-10-20

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2263109C2 (en) * 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн DERIVATIVES OF CARBOXYLIC ACIDS (VARIANTS), PHARMACEUTICAL COMPOSITION AND METHOD FO SELECTIVE BINDING α4β1-INTEGRIN IN MAMMAL
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
CN1646695A (en) 2002-02-12 2005-07-27 夸克生物技术公司 Use of the AXL receptor for diagnosis and treatment of renal disease
JP2009507080A (en) 2005-09-07 2009-02-19 リゲル ファーマシューティカルズ，インコーポレーテッド Triazole derivatives useful as Axl inhibitors
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
AU2006323027B2 (en) 2005-12-05 2012-08-02 Pfizer Products Inc Method of treating abnormal cell growth
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2656496T3 (en) 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as AXL inhibitors
CA2710046C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US7709482B2 (en) 2006-12-29 2010-05-04 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
EP2114955B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
WO2009007749A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011500778A (en) * 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ Pyridine and pyrazine derivatives-083
RU2010120536A (en) * 2007-10-25 2011-11-27 Астразенека Аб (Se) Pyridine and pyrazine derivatives useful for the treatment of cellular cellular disorders
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009058801A1 (en) 2007-11-02 2009-05-07 Janssen Pharmaceutica, N.V. Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
NZ586630A (en) 2008-01-23 2011-12-22 Bristol Myers Squibb Co 4-Pyridinone compounds and their use for cancer
US8558000B2 (en) 2008-01-23 2013-10-15 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US9206130B2 (en) 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
UY31800A (en) 2008-05-05 2009-11-10 Smithkline Beckman Corp CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR
WO2009138799A1 (en) 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2537480T3 (en) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
CN102307875A (en) 2009-02-09 2012-01-04 苏伯俭股份有限公司 Pyrrolopyrimidinyl axl kinase inhibitors
SG175355A1 (en) * 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds

Also Published As

Publication number Publication date
DK2810937T3 (en) 2017-03-13
HRP20170303T1 (en) 2017-04-21
TW201335148A (en) 2013-09-01
PH12014501719A1 (en) 2014-11-10
AU2013216006B2 (en) 2017-06-08
KR102078530B1 (en) 2020-02-18
US8933103B2 (en) 2015-01-13
ZA201405486B (en) 2015-11-25
RU2632885C2 (en) 2017-10-11
MY165215A (en) 2018-03-09
RU2014135401A (en) 2016-03-20
KR20140117439A (en) 2014-10-07
HUE031624T2 (en) 2017-07-28
CY1118656T1 (en) 2017-07-12
RS55728B1 (en) 2017-07-31
SMT201700065B (en) 2017-03-08
BR112014018702A8 (en) 2017-07-11
MX351812B (en) 2017-10-27
LT2810937T (en) 2017-02-10
TWI537259B (en) 2016-06-11
ES2617484T3 (en) 2017-06-19
WO2013115280A1 (en) 2013-08-08
EP2810937B1 (en) 2016-11-30
CN104185627B (en) 2018-01-12
JPWO2013115280A1 (en) 2015-05-11
EP2810937A1 (en) 2014-12-10
CO7071126A2 (en) 2014-09-30
MX2014009246A (en) 2014-10-14
JP6006241B2 (en) 2016-10-12
CN104185627A (en) 2014-12-03
HK1203504A1 (en) 2015-10-30
IL233863A0 (en) 2014-09-30
IL233863A (en) 2017-08-31
EP2810937A4 (en) 2015-07-22
BR112014018702A2 (en) 2017-06-20
PH12014501719B1 (en) 2014-11-10
AU2013216006A1 (en) 2014-08-28
US20130281428A1 (en) 2013-10-24
PL2810937T3 (en) 2017-07-31
SI2810937T1 (en) 2017-01-31
NZ627586A (en) 2016-08-26
PT2810937T (en) 2017-03-03
CA2863515A1 (en) 2013-08-08
CA2863515C (en) 2018-02-27

Similar Documents

Publication Publication Date Title
HRP20180451T1 (en) Pyridine derivative
HK1203504A1 (en) Pyridone derivative
HRP20180672T1 (en) Novel pyridine derivatives
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
IL236295A (en) Indanesulfamide derivative
PL2873660T3 (en) Indolecarboxamide derivative
EP2842958A4 (en) Naphthobisthiadiazole derivative
HK1215569A1 (en) Pyridone compound
HK1206716A1 (en) Novel pyridine derivatives
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-